Holen Sie sich die Stockscreener-App
70.66
0.34%
-0.265
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$70.92
Offen:
$70.92
24-Stunden-Volumen:
2.74M
Relative Volume:
0.64
Marktkapitalisierung:
$11.01B
Einnahmen:
$1.21B
Nettoeinkommen (Verlust:
$109.52M
KGV:
101.49
EPS:
0.6962
Netto-Cashflow:
$269.60M
1W Leistung:
+0.04%
1M Leistung:
+35.94%
6M Leistung:
+8.65%
1J Leistung:
+37.14%
1-Tages-Spanne:
$70.65
$70.98
1-Wochen-Bereich:
$70.56
$71.00
52-Wochen-Spanne:
$43.20
$72.16
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
612-379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
70.66 | 11.04B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
524.31 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.45 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.25 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.68 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-07-22 | Fortgesetzt | Stephens | Overweight |
| 2025-07-09 | Eingeleitet | TD Cowen | Buy |
| 2025-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Halper Sadeh LLC is Investigating Whether ACA, TECH, IRDM, LCII are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Activist investor Ananym urges Bio-Techne to consider selling - MSN
April McClain Delaney Makes Significant Trades in Bio-Techne Corp, C.H. Robinson Worldwide, and Transdigm Group - Investing.com
List of 18 Acquisitions by Bio-Techne (Jul 2026) - Tracxn
Merck KGaA to acquire Bio-Techne in $11.3 billion deal - qz.com
TECH Downgraded by Benchmark -- Rating Changed to Hold - GuruFocus
TECH Downgraded by TD Cowen -- Price Target Raised to $73.00 - GuruFocus
$64.99 support anchors Bio-Techne stock near current levels - Traders Union
Germany’s Merck to acquire Bio-Techne in $11.3 billion deal - MSN
Merck KGaA to acquire U.S.-based Bio-Techne Corp. for $11.3 billion - chemengonline.com
TECH Downgraded by Citigroup -- Rating Changed to Neutral - GuruFocus
German conglomerate Merck buys Minnesota firm Bio-Techne for $11.3B, one of largest deals in state history - Times West Virginian
Is Bio-Techne stock underperforming the S&P 500? - MSN
Germany's Merck to buy Bio-Techne for $73 per share - MSN
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history - MSN
Germany's Merck to buy Bio-Techne for $11.3 billion - MSN
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal - MSN
Price to sales forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to book forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Merck KGaA Strikes USD 11.3 Billion Bio-Techne Acquisition to Expand Life Sciences Portfolio - Medical Dialogues
Bio-Techne Soars Over 20% on Merck Acquisition News - Intellectia AI
Enterprise value to EBIT forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Price to earnings forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
TECH Maintained by Baird -- Price Target Raised to $73.00 - GuruFocus
TECH Downgraded by William Blair -- Rating Changed to Market Per - GuruFocus
Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion - MSN
Enterprise value to revenue forward of Bio-Techne Corp – NASDAQ:TECH - TradingView
Bio-Techne Corporation Actuals & Estimates (NASDAQ:TECH) - TradingView
Merck KGaA’s $11.3 Billion Bet on Bio-Techne Redraws the Map of Life-Science Tools - Oncodaily
Taxation With Representation: Sidley, Paul Weiss, Kirkland - Law360
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH) - PR Newswire
Merck KGaA to acquire Bio-Techne in $11.3bn deal to strengthen life sciences leadership - leadersleague.com
TECH Downgraded by Stephens & Co. -- Price Target Raised to $73. - GuruFocus
Merck KGaA Acquires Bio-Techne Corporation for 11.3 Billion Dollars - HarianBasis.co
Deutsche Bank cuts Bio-Techne stock rating on Merck acquisition By Investing.com - Investing.com Nigeria
Merck KGaA Doubles Down On Life Sciences With $11.3bn Bio-Techne Buyout - Citeline News & Insights
Bio-Techne Corporation (TECH) Merck KGaAM&A CallSlideshow (NASDAQ:TECH) 2026-06-26 - Seeking Alpha
Stephens Downgrades Bio-Techne to Equal Weight From Overweight, Adjusts Price Target to $73 From $68 - marketscreener.com
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout - Yahoo Finance
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets - marketscreener.com
Merck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocks - MSN
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Raises Price Target to $73 From $66 - marketscreener.com
Merck KGaA's Bio-Techne Deal Seems a Strong Fit -- Market Talk - Moomoo
Deutsche Bank Downgrades Bio-Techne to Hold From Buy, Adjusts Price Target to $73 From $66 - marketscreener.com
Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain CircumstancesSEC Filing - TradingView
Bio-Techne (TECH) Sees Significant Price Surge - GuruFocus
Merck KGaA (MKGAF) Acquires Bio-Techne (TECH) for $73 per Share - GuruFocus
Merck to buy Bio-Techne (NASDAQ: TECH) in $73 per share all-cash deal - Stock Titan
Bio-Techne retention bonuses approved for Kim Kelderman, Jim Hippel - TradingView
Merck Pulls Off Biggest Deal in a Decade With $11.3 Billion Bio-Techne Acquisition - finance.biggo.com
5 Stocks Winning by Double Digits - Insider Monkey
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
May 08 '26 |
Sale |
48.28 |
6,636 |
320,386 |
200 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):